NCAPG and breast cancer: Another study reported that NCAPG was significantly overexpressed in trastuzumab-resistant HER2+ breast cancer samples and that the upregulation of NCAPG was associated with poor survival and recurrence in patients with HER2+ breast cancer [13]; thus, to further determine whether NCAPG promotes LUAD progression, we designed a series of studies.